Table 5.
Cohort 1 of 17 NSCLC Patients and 10 Cancer-Free Controls | Cohort 2 of 69 NSCLC Patients and 79 Cancer-Free Controls | |||
---|---|---|---|---|
Sensitivity | Specificity | Sensitivity | Specificity | |
Combined Acidovorax and Veillonella for SCC | 80.79% | 89.08% | 75.76% | 88.61% |
Capnocytophaga for AC | 72.70% | 85.28% | 69.44% | 84.42% |
Acidovorax for distinguishing SCC from AC | 63.64% | 96.30% | 66.67% | 89.86% |